Mineralys Therapeutics, Inc.
$25.06
-19%Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -10.9).
Valuation inputs: P/E -10.9, earnings yield N/A, momentum -19.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -23.9%, ROIC -26.4%).
Profitability stack: net margin 0.0%, ROE -23.9%, ROIC -26.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +2.3%, momentum -19.4%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Mineralys Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Mineralys Therapeutics, Inc. Fair Value Envelope
No Revenue Data
MLYS has not reported any revenue values in the available annual periods.
Mineralys Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
MLYS has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
MLYS has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
MLYS has not reported any net profit margin values in the available annual periods.
Mineralys Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Mineralys Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Mineralys Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that MLYS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 46.00, with estimates ranging from a low of 30.00 to a high of 56.00.
The consensus 1-year price target stands at 46.00, with estimates ranging from a low of 30.00 to a high of 56.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Mineralys Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $53.76M and sold $60.75M worth of MLYS shares, resulting in $6.98M of net selling activity.
3 Months
369.0K
8.76M
100.7K
2.72M
+6.0M
+$6.04M
3-6 Months
0
0.00
246.3K
8.54M
-8.5M
-$8.54M
6-9 Months
0
0.00
1.1M
48.30M
-48.3M
-$48.30M
9-12 Months
1.8M
45.00M
82.9K
1.18M
+43.8M
+$43.81M
Top Buyers
Ra Capital Management, L.P.
Director
$38.76M
Akkaraju Srinivas
Director
$15.00M
Top Sellers
Slingsby Brian Taylor
Director, 10 Percent Owner:
$43.35M
Rodman David Malcom
Officer: Chief Medical Officer
$11.05M
Congleton Jon
Director, Officer: Chief Executive Officer
$3.05M
Levy Adam Scott
Officer: Cfo And Secretary
$2.15M
Gold Alexander M
Director
$919K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $6.98M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
No Dividend Yield Data
MLYS has not reported any dividend yield values in the available annual periods.
mlys Dividend History
Learning Layer
Related Guides
Build conviction on MLYS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.